



CONSEGNA
DELIVERING INNOVATION

Turning life science technologies into high value assets

Investor Update

Mr. Fabio Pannuti, Managing Director

Consegna Group Ltd (ASX:CGP)

June 2012



CONSEGNA
DELIVERING INNOVATION

Safe Harbour Statement

This document contains certain forward-looking statements, relating to CGP's business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. CGP is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



Consegna Group - Key Facts


Board and Management

Rod Tomlinson	Chairman
Fabio Pannuti	CEO & MD
Andrew Ellem	CFO
Dr Nick Ede	CTO
Lord Simon Reading	Non-Exec Director
Brendan Fleiter	Non-Exec Director
Justyn Stedwell	Company Secretary

Key Statistics (06 June 2012)

ASX Code	CGP
Current Share Price	A\$0.021
52 week high	A\$0.05
52 week low	A\$0.02
Shares on issue	934 Million
Market capitalisation	A\$23.75 million

Consegna Business Model



Consegna Packaging Hypothesis

- Systematic identification and mitigation of core risks associated with the commercialisation of a technology

- Delivers an increase in value of the assets under management across the entire portfolio during development

- Provides partners with a more valuable 'close to revenue' franchise rather than a latent technology


- Delivers Consegna higher upfront licensing fees and short - medium term royalty streams

Consegna Packaging Process




Multiple Market Opportunities

Each of the Consegna technologies has application across a range of market opportunities:



Comparator Valuations/Transactions

Consegna Portfolio 2012		Comparators
Vibrovein™		Prefilled syringe market project to be worth \$3.19b in 2015 ⁴
BreatheAssist™		CNS owner of BreathRight bought by GSK for US\$566m ¹
Linguet™		Generex licenses its Buccal technology for \$10m to Amaranthus BioSciences ³
Aspen Medisys		Sirtex “SirSpheres” technology. Market Cap AU\$288m ² , \$72m rev.



Consegna team has historically monetised \$1billion+ of medical products and are in the process of packaging the Consegna Portfolio.




CONSEGNA
DELIVERING INNOVATION

Technology Portfolio


LINGUET

- TRANSACTING WITH IMU



- Linguet™ – buccal (orodispersible) tablet delivery technology with increased drug load capacity
 - Technology acquisition transaction closed August 2011 (50K debt forgiveness and 24Mil CGP shares);
 - Transacting with Imugene (ASX:IMU) in June 2012 (100Mil IMU shares) – *subject to shareholders approval at July EGM;*
 - Mr Fabio Pannuti, currently the Managing Director of Consegna will join the Imugene board as an Executive Director;
 - Imugene will engage with the Consegna scientific team to assist in the development of the Linguet™ technology (services agreement);
 - Clear commercialization strategy to deliver short term revenues and significant long term growth; and
 - Proposed in specie share distribution to Consegna shareholders.

Technology Portfolio



BREATHEASSIST

- IN LICENSING DISCUSSIONS WITH MULTINATIONAL PARTIES

- BreatheAssist™ – new multi-functional nasal dilation technology
 - Breathe Right™ technology owner CNS Inc. was acquired in 2006 by GSK for US \$566m on \$100m sales;
 - Development of prototype completed;
 - Regulatory clearance obtained;
 - Initial performance testing completed;
 - Multiple transaction opportunities: sports performance, snoring / sleep apnoea, filtration and drug delivery;
 - Near-term milestones (Q312):
 - Complete design for manufacture and scale-up; and
 - Complete sports performance testing and undertake prelaunch activities (Olympic program).
 - Continuing licensing discussions with several multinational parties

BreatheAssist: Go-to-market strategy locked in

BREATHEASSIST STRATEGY – sport provides us with a ‘fast to market’ entry and product familiarisation

Technology Validation

Consumer study nearing completion
Sport clinical trial beginning in July (ethics approval obtained).

Regulatory pathway

Cleared for sale as a consumer product into US, EU and Australian markets


Currently in process for Class 1 device registration (snoring/sleep apnea markets).

Business Development

Cost of goods locked in and modelled. Discussions underway with big pharma and other parties.

Platform Expansion and Revenue Growth

Develop clinical and commercial program for sleep and drug/non-drug delivery.



Technology Portfolio

VIBROVEIN

- ADDRESSING SPIN OUT
- TARGETED PRODUCT LAUNCH Q3, 2013

- Vibrovein™ – Injection technology delivering accuracy, efficiency and significant pain reduction
 - Preliminary proof of concept study at Oxford complete;
 - Further proof of technology work completed by Danaher/Invetech;
 - Follows design perfection: mosquito;
 - Over 5 years of clinical use;
 - Multiple transaction opportunities: initial targets include \$44m sclerotherapy market (US alone) and the billion dollar Cosmetic surgery market (Botox);
 - Near-term milestones:
 - Complete design for manufacture and scale-up; and
 - Complete commercial prototype & utility validation.
 - Targeted product launch in US market, Q3, 2013

Vibrovein: sclerotherapy delivers an addressable entry market and short term revenues

VIBROVEIN STRATEGY – clear path to market

Technology Validation

Validated by clinician in sclerotherapy and cosmetic applications.

Strong response from practitioners in phlebology conference (May 2012).

Regulatory pathway

Gaining advice as to status within the US and EU markets.

Business Development


Finalise current model ready for AUS market after medical device registration.

Target product launch at major phlebology conference Q3, 2013

Platform Expansion

Begin design of disposable insulin syringe/pen for paediatric market.

Technology Portfolio



ASPEN

- CONTINUED PACKAGING OF ASSET
- IN DISCUSSIONS REGARDING JOINT VENTURE WITH RUSSIAN GROUP

- Aspen MediSys, LLC – venture-backed, US-based nanotechnology company;
- Acquisition transaction closed December 2011;
- Novel, proprietary medical device technology utilizes magnetic nanoparticles to precisely target and destroy solid tumors upon activation by external magnetic field: local heat generation (thermotherapy);
- Proof-of-concept completed;
- Near-term milestones:
 - Commence efficacy study in companion animals; and
 - Continuing discussions with Russian group regarding possible JV
 - Vending out through IP or trade sale

Aspen summary: strong patent position in the US for thermotherapy platform

ASPEN STRATEGY – leverage the strength of US patents to commercialise technology

Technology Validation

Platform to be validated in companion animal market near term, leading to first in human trials 2014.

IP Optimisation

Clear IP position identified. Strong US market focus and potential.

Business Development

Focus on adding value to platform in the thermotherapy market. Currently identifying leading business partners for partnering.

In discussions regarding new JV with Russian group.

Platform Expansion

2020 plus for launch in US in human oncology treatment.



For more information contact:

Fabio Pannuti

Managing Director

fpannuti@consegna.com